NASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis $0.39 +0.03 (+6.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.39 0.00 (-0.54%) As of 09/12/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Femasys Stock (NASDAQ:FEMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Femasys alerts:Sign Up Key Stats Today's Range$0.37▼$0.4050-Day Range$0.36▼$0.9752-Week Range$0.31▼$1.80Volume1.22 million shsAverage Volume2.77 million shsMarket Capitalization$12.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company Overview Femasys International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care. The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools. Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.AI Generated. May Contain Errors. Read More Femasys Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreFEMY MarketRank™: Femasys scored higher than 62% of companies evaluated by MarketBeat, and ranked 418th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingFemasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialFemasys has a consensus price target of $7.33, representing about 1,770.3% upside from its current price of $0.39.Amount of Analyst CoverageFemasys has only been the subject of 1 research reports in the past 90 days.Read more about Femasys' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Femasys are expected to grow in the coming year, from ($0.86) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Femasys' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.85% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently increased by 327.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.85% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently increased by 327.68%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.74 News SentimentFemasys has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Femasys this week, compared to 2 articles on an average week.Search Interest6 people have searched for FEMY on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders11.54% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Femasys' insider trading history. Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FEMY Stock News HeadlinesFemasys expands FemSperm product line with Insemination Prep KitSeptember 11 at 1:33 PM | msn.comFemasys Inc. Launches FemSperm Insemination Prep Kit to Enhance Accessibility of Fertility TreatmentsSeptember 11 at 9:30 AM | quiverquant.comQTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 13 at 2:00 AM | Porter & Company (Ad)Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®September 11 at 9:00 AM | globenewswire.comFemasys secures MEDSAFE approval for FemBloc Permanent Birth ControlSeptember 9, 2025 | msn.comFemasys Inc. Receives MEDSAFE Approval for FemBloc Permanent Birth Control in New Zealand, Expanding Global Access to Innovative Women's Health SolutionsSeptember 8, 2025 | quiverquant.comQFemasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New ZealandSeptember 8, 2025 | globenewswire.comFemasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control PortfoliosSeptember 2, 2025 | finance.yahoo.comSee More Headlines FEMY Stock Analysis - Frequently Asked Questions How have FEMY shares performed this year? Femasys' stock was trading at $1.10 at the beginning of 2025. Since then, FEMY stock has decreased by 64.4% and is now trading at $0.3921. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) announced its quarterly earnings results on Friday, August, 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business earned $0.41 million during the quarter, compared to analyst estimates of $0.80 million. Femasys had a negative net margin of 1,113.72% and a negative trailing twelve-month return on equity of 713.74%. When did Femasys IPO? Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading served as the underwriters for the IPO. Who are Femasys' major shareholders? Femasys' top institutional investors include Clear Creek Financial Management LLC (0.87%), Jane Street Group LLC (0.26%) and Osaic Holdings Inc. (0.14%). View institutional ownership trends. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Femasys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE). Company Calendar Last Earnings8/08/2025Today9/13/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEMY CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Femasys$7.33 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+1,770.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.82 million Net Margins-1,113.72% Pretax Margin-1,113.30% Return on Equity-713.74% Return on Assets-152.60% Debt Debt-to-Equity Ratio0.03 Current Ratio0.89 Quick Ratio0.41 Sales & Book Value Annual Sales$1.63 million Price / Sales7.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.92Miscellaneous Outstanding Shares32,580,000Free Float28,816,000Market Cap$12.77 million OptionableNot Optionable Beta-2.64 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:FEMY) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.